ClinicalTrials.gg
CompletedNCT07450482Updated Mar 4, 2026

Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD

A Phase 2 interventional study of JKN2304 Inhalation Solution and Placebo in COPD (Chronic Obstructive Pulmonary Disease) and COPD, sponsored by Joincare Pharmaceutical Group Industry Co., Ltd. Completed at 8 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Joincare Pharmaceutical Group Industry Co., Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jul 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 111 open to participants now, 128 under way, 16 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Enrollment
223rd of 289
42 · median 160
Started
2025
with 41 others
Phase 2
33 of 407
13 open now
Registered
371st of 407
by date

Among the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 223rd largest by enrollment of the 289 interventional ones that give a count, is one of 42 that started in 2025, is one of 33 in phase 2, and was the 371st registered.

Pulmonary Disease, Chronic Obstructive

5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

111 of the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

The purpose of this Phase IIa study is to evaluate the safety, efficacy, and pharmacokinetics of JKN2304 Inhalation Solution in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). The study is a multicenter, randomized, double-blind, placebo-controlled, and active-controlled (open-label) trial. Participants are randomized to receive JKN2304 (2 mg once daily or 2 mg twice daily), Placebo, or Formoterol Fumarate Inhalation Solution for a treatment period of 14 days.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled, and active-controlled (open-label for the active comparator) Phase IIa clinical study. The study aims to enroll approximately 40 patients with moderate to severe stable Chronic Obstructive Pulmonary Disease (COPD).

The study consists of three periods: a Screening Period (up to 28 days), a Treatment Period (14 days), and a Follow-up Period (7 days).

During the Screening Period, patients undergo wash-out of prohibited medications (e.g., LAMA withdrawn for at least 7 days, LABA for at least 48 hours prior to the reversibility test). Eligible participants are randomized in a 1:1:1:1 ratio to one of the following four treatment arms:

  1. JKN2304 Inhalation Solution 2 mg QD (Once Daily): 2 mg active drug in the morning and placebo in the evening.
  2. JKN2304 Inhalation Solution 2 mg BID (Twice Daily): 2 mg active drug in the morning and 2 mg active drug in the evening.
  3. Placebo Control: Placebo in the morning and placebo in the evening.
  4. Active Control: Formoterol Fumarate Inhalation Solution 20 μg BID (Open-label). The primary objective is to evaluate the safety of JKN2304 in COPD patients. Secondary objectives include evaluating the efficacy (assessed by pulmonary function tests such as FEV1) and characterizing the pharmacokinetic (PK) profile of JKN2304.

Safety assessments are conducted throughout the study. Efficacy assessments, including pulmonary function tests, are performed at designated time points (e.g., Day 1 and Day 14). A safety follow-up visit is conducted on Day 21 (7 days after the last dose).

03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)
  • COPD

Keywords

  • COPD
  • Chronic Obstructive Pulmonary Disease
  • JKN2304
  • Moderate to Severe COPD
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and comply with the trial procedures, voluntarily participate, and sign the form.
  2. Age between 40 and 75 years (inclusive) at the time of signing the informed consent, both males and females.
  3. History of exposure to risk factors, such as: smoking history ≥10 pack-years (pack-years = [number of cigarettes per day / 20] x years smoked; use of electronic cigarettes, pipes, or cigars cannot be used to calculate pack-years), or exposure to biomass fuel for ≥10 years.
  4. Established diagnosis of COPD according to the GOLD 2024 guidelines prior to screening.
  5. History of ≥1 severe Acute Exacerbation of COPD (AECOPD) leading to hospitalization OR ≥2 moderate AECOPDs within 12 months prior to screening; OR, if ≤1 moderate AECOPD within 12 months prior to screening, then baseline mMRC score must be ≥2 and CAT score ≥10.
  6. No occurrence of AECOPD within the 4 consecutive weeks prior to screening.
  7. Post-bronchodilator (400 µg salbutamol) /FVC \< 0.70, and post-bronchodilator FEV1 percent predicted (ppFEV1) between 30% and 79%.
  8. Ability to perform acceptable and reproducible spirometry.
  9. Compliance with concomitant medication restrictions (see study protocol section 5.6) and expected to maintain these restrictions during the treatment period.
  10. For subjects of (or with partners of childbearing potential), willingness to use effective from signing the informed consent until 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. History of to the drug or drugs of the same class, or history of bronchospasm.
  2. Current diagnosis of bronchial asthma.
  3. Current diagnosis of other lung diseases that may impair lung function, including but not limited to: alpha-1 antitrypsin deficiency, cystic fibrosis, bronchiectasis, bronchiolitis obliterans, bronchopulmonary dysplasia, active pulmonary tuberculosis, pulmonary hypertension (except if judged by the investigator to be due to ), interstitial lung disease (e.g., pulmonary fibrosis), pneumothorax, etc.
  4. Acute lower respiratory tract infection within 4 weeks prior to or during screening.
  5. Hospitalization for respiratory disease within 4 weeks prior to or during screening.
  6. history of cardiovascular/cerebrovascular disease within 6 months prior to screening, such as congestive heart failure, acute coronary syndrome (including acute myocardial infarction and unstable angina), newly diagnosed atrial fibrillation, supraventricular/ventricular tachycardia, aortic aneurysm, stroke, etc.
  7. Poorly controlled hypertension within 6 months prior to screening (defined as failure to achieve target blood pressure despite combination therapy with ≥3 antihypertensive agents) OR confirmed systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg during screening upon repeated measurement; severe arrhythmia requiring antiarrhythmic drug therapy; sinus node dysfunction, Mobitz type II or third-degree atrioventricular block without a pacemaker.
  8. Narrow-angle glaucoma, bladder neck obstruction, moderate-to-severe prostatic hyperplasia, or history of acute urinary retention, judged by the investigator as a to inhaled anticholinergic drugs.
  9. Any active or history of malignancy within 5 years prior to screening, except for cured cancers (e.g., basal cell carcinoma, squamous cell carcinoma of the skin, localized low-risk prostate cancer, papillary thyroid carcinoma) and radically resected carcinoma in situ (e.g., ductal carcinoma in situ of the breast, cervical carcinoma in situ).
  10. Laboratory values at screening meeting any of the following:

    1. (NEUT) \< 1.5 x 10\^9/L
    2. > 2.5 x OR AST > 2.5 x ULN OR Total > 1.5 x ULN
    3. Creatinine (Cr) > 1.5 x ULN
  11. History of long syndrome, or QTc > 480 ms at screening (calculated using Fridericia's formula: QTc = QT / RR\^0.33).
  12. History of lung resection surgery, or lung volume reduction surgery within 12 months prior to screening.
  13. On long-term regular oxygen therapy (>12 hours/day) or mechanical ventilation at screening.
  14. Initiation of a pulmonary rehabilitation program within 4 weeks prior to screening or planned initiation during the study.
  15. Use of long-acting bronchodilators (including LABA and LAMA) prior to screening, if judged by the investigator as unable to discontinue for at least 14 days prior to the first dose or during the study.
  16. Use of inhaled (ICS) prior to screening, meeting any of the following:

    1. Planning to continue during the study AND dose stable for \<28 days prior to the first dose; OR originally on combination ICS and unwilling to switch to an equivalent dose of monotherapy ICS during the study.
    2. Planning to discontinue during the study AND discontinued for \<28 days prior to the first dose.
  17. Use of oral theophylline or leukotriene inhibitors prior to screening, meeting any of the following:

    1. Planning to continue during the study AND dose stable for \<28 days prior to the first dose.
    2. Planning to discontinue during the study AND discontinued for less than 5 half-lives of the respective drug prior to the first dose.
  18. Participation in another clinical trial within 28 days prior to screening or between V1-V3, or within 5 half-lives of the previous investigational drug (whichever is longer; participation defined as having received study drug).
  19. History of alcohol abuse (weekly intake >14 units: 1 unit ≡ 285 mL beer, 25 mL spirits, or 100 mL wine) or drug abuse within 6 months prior to screening.
  20. History of psychiatric disorder or cognitive impairment.
  21. Major surgery within 28 days prior to screening or planned major surgery during the study.
  22. Female subjects who are lactating or pregnant, or with positive blood HCG at screening.
  23. Any other condition considered by the investigator as unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    JKN2304 2 mg QD

    Participants receive JKN2304 Inhalation Solution 2 mg in the morning and Placebo in the evening via nebulizer for 14 days.

    Drug: JKN2304 Inhalation Solution · Other: Placebo

  • Experimental
    JKN2304 2 mg BID

    Participants receive JKN2304 Inhalation Solution 2 mg in the morning and JKN2304 Inhalation Solution 2 mg in the evening via nebulizer for 14 days.

    Drug: JKN2304 Inhalation Solution

  • Placebo comparator
    Placebo

    Participants receive Placebo (JKN2304 simulator) in the morning and evening via nebulizer for 14 days.

    Other: Placebo

  • Active comparator
    Formoterol Fumarate

    Participants receive Formoterol Fumarate Inhalation Solution 20 μg twice daily (morning and evening) via nebulizer for 14 days. (Open-label)

    Drug: Formoterol Fumarate Inhalation Solution

Interventions

  • DrugJKN2304 Inhalation Solution

    Specification: 3ml:2mg. Administered via nebulizer.

  • OtherPlacebo

    Specification: 3ml:0mg. Matches the appearance of the investigation product. Administered via nebulizer.

  • DrugFormoterol Fumarate Inhalation Solution

    Specification: 2ml:20μg. Administered via nebulizer.

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Assessment of safety including adverse events, laboratory tests (hematology, blood biochemistry, urinalysis), electrocardiogram (ECG), vital signs, physical examinations, and oropharyngeal examinations.

    Time frame: From signing of informed consent through the safety follow-up visit (Day 21)

Secondary outcomes

  1. Change from Baseline in FEV1 AUC0-3h

    Area Under the Curve (AUC) for Forced Expiratory Volume in 1 second (FEV1) from 0 to 3 hours post-dose.

    Time frame: Day 14

  2. Change from Baseline in Peak FEV1

    Change in maximum FEV1 observed post-dose.

    Time frame: Day 1 and Day 14

  3. Change from Baseline in Trough FEV1

    Trough FEV1 measured at the end of the dosing interval (12 hours post-evening dose for BID regimen, or 24 hours post-dose for QD regimen as applicable per protocol definition).

    Time frame: Day 1, Day 6, and Day 14

  4. Change from Baseline in FEV1 AUC0-12h and AUC0-24h

    Area Under the Curve for FEV1 from 0 to 12 hours and 0 to 24 hours post-dose.

    Time frame: Day 1 and Day 14

  5. Change from Baseline in COPD Assessment Test (CAT) Score

    The COPD Assessment Test (CAT) is a patient-completed questionnaire assessing the impact of COPD on health status. The scale ranges from 0 to 40, where higher scores indicate a worse outcome (greater impact of COPD on the patient's life).

    Time frame: Day 7 and Day 15

  6. Change from Baseline in Modified Medical Research Council (mMRC) Dyspnea Scale Score

    The Modified Medical Research Council (mMRC) Dyspnea Scale assesses the degree of breathlessness. The scale ranges from Grade 0 to Grade 4, where higher grades indicate a worse outcome (more severe breathlessness).

    Time frame: Day 7 and Day 15

  7. Percentage of Participants Using Rescue Medication

    Proportion of participants requiring Salbutamol Sulfate Aerosol for rescue therapy.

    Time frame: Up to Day 14

  8. Area Under the Plasma Concentration-Time Curve (AUC) of JKN2304

    Area under the plasma concentration-time curve from time zero to the end of the dosing interval at steady state (AUC0-t).

    Time frame: Day 1 and Day 13-15 (per sampling schedule)

  9. Maximum Plasma Concentration (Cmax) of JKN2304

    Peak plasma concentration of JKN2304 observed at steady state.

    Time frame: Day 1 and Day 13-15 (per sampling schedule)

  10. Time to Maximum Plasma Concentration (Tmax) of JKN2304

    Time from drug administration to maximum observed plasma concentration at steady state.

    Time frame: Day 1 and Day 13-15 (per sampling schedule)

  11. Trough Plasma Concentration (Ctrough) of JKN2304

    Plasma concentration of JKN2304 measured at the end of the dosing interval (trough).

    Time frame: Day 1 and Day 13-15 (per sampling schedule)

07

Study locations

8 sites
  • Zhangzhou Hospital, Fujian Province
    Zhangzhou, Fujian, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong, China
  • Liuyang People's Hospital
    Guankou, Hunan, China
  • Jiangyin Hospital of Traditional Chinese Medicine
    Jiangyin, Jiangsu, China
  • The Affiliated Hospital of Yangzhou University
    Yangzhou, Jiangsu, China
  • Weifang Second People's Hospital
    Weifang, Shandong, China
  • Huadong Hospital Affiliated to Fudan University
    Shanghai, Shanghai Municipality, China
  • Shanghai Pudong New Area People's Hospital
    Shanghai, Shanghai Municipality, China
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) and supporting clinical documents from this Phase IIa study will not be made publicly available. The decision is based on the following considerations: 1) The data are preliminary and derived from a small, exploratory study, intended primarily for internal research and development and regulatory submission purposes. 2) The dataset contains detailed participant-level information that could compromise participant privacy and confidentiality. 3) Data sharing is restricted in accordance with applicable privacy laws and regulations in China. Future data sharing policies for subsequent phases of the clinical development program may be re-evaluated.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Sep 2025, 2 months.

Of 119 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 2 months is below that.

Counting every sponsor, half of 166 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Mar 4, 2026
StartActual
Jul 22, 2025
Primary completionActual
Sep 25, 2025
CompletionActual
Sep 25, 2025
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07450482
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Jul 22, 2025
Primary completion
Sep 25, 2025
Completion
Sep 25, 2025
Last update
Mar 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion